Collaborative and Other Relationships - Samsung Bioepis (Details) $ in Millions	1 Months Ended						12 Months Ended
	Oct. 31, 2025 USD ($)	Mar. 31, 2025 USD ($)	Jul. 31, 2024	Apr. 30, 2024 USD ($)	Apr. 30, 2022 USD ($)	Dec. 31, 2019 product	Dec. 31, 2025 USD ($) payment	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Apr. 30, 2023 USD ($)
Collaborative arrangements and non-collaborative arrangement transactions
Number of ophthalmolgy biosimilar products | product						2
Impairment of intangible assets							$ 7.9	$ 60.2	$ 0.0
Collaboration profit sharing/(loss reimbursement)							290.2	254.4	218.8
Revenue							$ 9,890.6	9,675.9	9,835.6
Proceeds from sale of intangible assets	$ 28.0	$ 51.0		$ 103.0
Samsung Bioepis
Collaborative arrangements and non-collaborative arrangement transactions
Proceeds from divestiture of interest in joint venture					$ 1,000.0
Due from joint venture					$ 1,300.0
Number of payments | payment							2
Expected profit share percentage						45.00%	50.00%
Impairment of intangible assets							$ 20.2
Term of collaboration agreement			10 years
Term of collaboration agreement, additional length			5 years
Option exercise fee							60.0
Collaboration profit sharing/(loss reimbursement)							219.2	227.4	223.5
Revenue							15.5	14.4	$ 13.6
Amounts receivable							4.4	7.6
Amounts payable							$ 42.7	$ 60.8
Samsung Bioepis | Payment Due At First Anniversary
Collaborative arrangements and non-collaborative arrangement transactions
Due from joint venture										$ 812.5
Samsung Bioepis | Payment Due At Second Anniversary
Collaborative arrangements and non-collaborative arrangement transactions
Due from joint venture				$ 437.5
Samsung Bioepis
Collaborative arrangements and non-collaborative arrangement transactions
Ownership percentage					49.90%
Amount sold					$ 2,300.0